TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Participants Must:~* Have a diagnosis of XSCID~* Be between 2 years to 20 years old and have not completed puberty~* Consent to permit blood and/or tissue samples for storage~* Demonstrate short stature: height below the 3 rd percentile for chronological age~* Have a primary care physician at home~* Demonstrate growth failure, defined as growth velocity (measured as linear growth) that is less than 5% to 10% of that expected for children of the same age group, over the past 12 months~* Willingness to remain hospitalized for several days~* Provide evidence of serum IGF-1 level performed within the preceding 6 months and the results fall below normal limits for age~EXCLUSION CRITERIA:~Participants Must NOT:~* Have fusion of epiphyseal plates~* Demonstrate any history of anaphylactic reaction or hypersensitivity to mecasermin or any component of the drug's formulation~* Have any active or suspected neoplasia~* Demonstrate signs of intracranial hypertension as evidenced by papilledema upon examination by fundoscopy~* Have any condition that, in the investigator's opinion, places the patient at undue risk by participating in the study~* Be unwilling to undergo testing or procedures associated with this protocol

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Darbepoetin in Contrast-induced Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 yr~* estimated glomerular filtration rate (GFR) \< 60 ml/min/1.73m2~Exclusion Criteria:~* Chronic renal replacement therapy (hemodialysis, peritoneal dialysis, continuous renal replacement therapy)~* Pregnancy or lactation~* Use of contrast agent within 1 week~* Emergent CAG or PCI~* Not recovered from AKI(acute kidney injury)~* Use of nephrotoxic drugs within 48 hr~* Cardiogenic shock (SBP(systolic blood pressure) \< 90 mmHg) or pulmonary edema~* Uncontrolled hypertension (SBP ≥ 200 mmHg or DBP(diastolic blood pressure) ≥ 130 mmHg)~* History of hypersensitivity to contrast agent~* Known allergy or hypersensitivity to EPO(erythropoietin)~* Use of EPO within 1 month~* Anemia (hemoglobin \< 9 g/dL)~* Ventilatory care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darbepoetin-α (Type: EXPERIMENTAL): Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
- isotonic saline (Type: PLACEBO_COMPARATOR): Infusion of isotonic saline will be performed 1 hour before angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Performance of Coronary CT Angiography With CT FFR in Kidney Transplantation Candidates

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Candidates for kidney transplantation on dialysis without any residual kidney function AND referred to invasive coronary angiography for cardiac evaluation~* Referral to invasive coronary angiography is based on algorithm used at the Transplant Readiness Assessment Clinic (TRAC) at Stanford:~* A. Diabetic Candidates older than 45 years.~* B. Diabetic Candidates under 45 years old and any one of the following criteria is present:~* a) 25 year History of Diabetes~* b) 5 year Smoking History~* c) Abnormal EKG (ST-T wave changes)~Exclusion Criteria:~* Hemodynamically and clinically unstable condition (angina at rest, malignant arrhythmias)~* Known ischemic heart disease (prior, documented myocardial infarction, prior stenting or coronary artery bypass graft surgery)~* BMI\>30 kg/m2, or weight \>120 kg.~* Atrial fibrillation or other arrhythmia, \>6 ectopic beats per minute~* Known or suspected allergy to iodinated contrast medium~* Pregnancy cannot be excluded

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated stage A CLL patients~* Healthy volunteers~Exclusion Criteria:~* Patients with other malignancies~* Patients receiving corticosteroids or other immunosuppressive drugs~* Patients who have received vaccination against influenza in the past 6 months~* Patients who have had an allergic reaction to a flu shot in the past, or have an allergy to eggs or who previously developed Guillain-Barré syndrome within 6 weeks of getting a flu shot~* Patients failing to give informed consent.~* Patients using homeopathic remedies such as echniaea cream.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A CLL patients (Type: ACTIVE_COMPARATOR): Vaccination with current trispecific influenza vaccine Day 1
- Group B CLL patients (Type: EXPERIMENTAL): Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
- Group C volunteers (Type: ACTIVE_COMPARATOR): Vaccination with current trispecific influenza vaccine Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Short-term Simulated Altitude Exposure on Cardiopulmonary Functional Capacity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female individuals aged 50-70 years with sedentary lifestyles.~Exclusion Criteria:~* Known intolerance to altitude identified by the participant's clinical examination, history and pre-altitude screening completed by the research clinician.~* Non-availability and/or suitability to complete the required residential period within the altitude centre.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Hypoxia (Type: EXPERIMENTAL): Mild hypoxia of 15% oxygen, equivalent altitude of 2440m over a period of 7 days
- Normoxia (Type: SHAM_COMPARATOR): Exposure to normal, sea-level air

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Progressive Splinting Status Post Elbow Fractures and Dislocations

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Extra or intraarticular distal humerus or elbow fracture or fracture/dislocation~* Agrees to participate and signs informed consent~* English Speaking (outcome questionnaires are validated for English only)~Exclusion Criteria:~* Less than 18 years of age~* Closed Head Injury~* Burn Injuries~* Ipsilateral upper extremity fracture(s) requiring surgery~* Nonunion of prior distal humerus fracture or fracture dislocation~* Type 3 open distal humerus fracture dislocation~* Insufficient fracture fixation to allow early range of motion~* Transient population with no fixed address~* Not willing to sign informed consent~* Does not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Joint Active Systems Brace (JAS Brace) (Type: EXPERIMENTAL): Elbow is placed in a brace to apply an extension force
- PT Only Group (Type: NO_INTERVENTION): No brace is used

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: YF476 and Type I Gastric Carcinoids (Norway)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients known to have gastric carcinoids associated with chronic atrophic gastritis and hypergastrinaemia, and who attend the outpatient clinic of the investigator;~* Men, postmenopausal women, premenopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophorectomy, or premenopausal women using reliable contraception: condom and spermicide or intrauterine device;~* Adults ≥ 18 years;~* Good general health; and~* Able to give fully-informed, written consent.~Exclusion Criteria:~* Women who are pregnant, lactating or using a steroid contraceptive;~* History of gastric surgery, apart from surgery for gastric carcinoids;~* Evidence of Zollinger-Ellison syndrome;~* Prolonged QTc interval (\>450 msec);~* Certain medicines and herbal remedies taken during the 7 days before visit 1;~* Previous treatment with somatostatin; or~* Participation in other clinical trials of unlicensed medicines within the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YF476 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lactobacillus GG Supplementation During Pediatric Burn Injuries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Burn wound size of at least 20% of the body surface area~* Requires antibiotic therapy~Exclusion Criteria:~* \< 20% total body surface area burn~* Does not require antibiotic therapy~* Only requires post-operative antibiotic therapy~* Bowel obstruction~* Milk allergy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with 4T's Score greater than or equal to 4.~Exclusion Criteria:~* Require ongoing anticoagulant therapy for a mechanical heart valve.~* Severe renal insufficiency (CrCl\<30 ml/min)~* Hepatic disease (including Child-Pugh B and C) associated with coagulopathy and a clinically relevant bleeding risk~* Inability to take oral medications.~* Ongoing requirement for systemic treatment with azole-antimycotics (except fluconazole) or HIV-protease inhibitors or strong CYP3A4 inducers~* Clinically significant active bleeding or lesions at increased risk for bleeding within the last 6 months~* Platelet count less than 80 and an ongoing need for antiplatelet therapy may be excluded at the discretion of the investigator~* Pregnant or a woman of child-bearing potential not using an adequate birth control method~* Hypersensitivity to rivaroxaban or to any ingredient in the formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Radiographically documented metastatic disease with evidence of disease progression Laboratory parameters per protocol~* Surgically or medically castrate~* Patients who have progressed following:~* a. at least initial therapy (chemotherapy or treatment with a hormonal agent known to impact survival such as abiraterone and enzalutamide); or~* b. one first-line chemotherapy regimen and one additional hormonal agent known to impact survival such as abiraterone and enzalutamide; or~* c. failure of two lines of chemotherapy; or~* d. failure of pre-chemotherapy abiraterone or enzalutamide and subsequent chemotherapy~Exclusion Criteria:~* Patients with neuroendocrine or small cell cancer of the prostate 2. History of other malignant disease (with the exception of the primary prostate cancer and non-melanoma skin tumors) in the past 5 years Pre-defined co-morbidities~* Administration of experimental therapy within the last 4 weeks before start of screening~* Treatment with immunotherapy within the last 3 months before start of screening~* Treatment with radiopharmaceutical drugs within 8 weeks before start of screening~* Receipt of oncolytic virus treatment or vaccination with a live virus within 4 weeks of study start~* History of organ transplantation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCVac and ONCOS-102 (Type: EXPERIMENTAL): ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed epithelioid predominantly (\> 70%) subtype malignant pleural mesothelioma~* Patient must have been evaluated by a University of California Los Angeles (UCLA) thoracic surgeon, and deemed medically and technically suitable for a pleurectomy/decortication procedure~* Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG) 0-2~* If a woman is of childbearing potential, a negative urine or serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study participation and for up to 4 weeks following the study~Exclusion Criteria:~* Patients who have previously received therapeutic radiation therapy to the chest~* Active systemic, pulmonary, or pericardial infection~* Use of chemotherapy within 4 weeks of the planned start of radiation therapy~* Pregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study~* Refusal to sign the informed consent~* Patients who are participating in a concurrent treatment protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (hypofractionated IMRT, pleurectomy/decortication) (Type: EXPERIMENTAL): Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic rejection defined by Banff 2007 criteria~Exclusion Criteria:~* Patients who have recurrent renal diseases and virus-associated renal diseases~* Patients who have initial WBC \< 4,000, neutrophil \< 1,000 , platelet \< 50,000 or Hb \< 8g~* Patients who have acute or chronic infection

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Deoxyspergualin, Treatment, (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacologic Modulation of Hippocampal Activity in Psychosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for psychosis subjects:~1. Men and women age 18 - 65.~2. Communicative in English.~3. Provide voluntary, written informed consent.~4. Physically healthy by medical history.~5. BMI \> 17.5 and \< 45.~6. Diagnosis of a psychotic disorder confirmed by Structured Clinical Interview for DSM-V (SCID) or diagnostic interview with a trained clinician.~7. Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.~8. For females, no longer of child-bearing potential, or agreeing to practice effective contraception during the study; and,~9. For females of child-bearing potential, must have negative urine pregnancy test at time of screening visit and before each testing day.~10. Not breastfeeding/nursing at time of screening or at any time during the study.~Inclusion criteria for healthy controls All of the above except for subjects will be psychiatrically healthy and not taking psychotropic or potentially psychoactive prescription medication.~Exclusion criteria for psychosis subjects~1. Age less than 18 or greater than 65.~2. Not communicative in English.~3. Unable to provide written informed consent.~4. Current medical or neurological illness.~5. History of severe head trauma.~6. BMI \< 17.5 or \> 45.~7. Meets criteria for diagnosis of substance or alcohol use disorder within the past month.~8. Positive urine pregnancy test at time of screening, before each testing day, or any potential concern for pregnancy at any time during the study.~9. Breastfeeding/nursing at time of screening or at any time during the study.~10. Conditions that preclude MR scanning~11. Conditions that preclude study drug administration~Exclusion criteria for healthy controls~All of the above and in addition:~1. Current use of psychotropic or potentially psychoactive prescription medication.~2. Major psychiatric disorder as determined by DSM-V (major depression, bipolar disorder, obsessive compulsive disorder, post-traumatic stress disorder, etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Levetiracetam (LEV) 500 mg (Type: EXPERIMENTAL): Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility